Podcasts about circulating

Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Get your essays ready for the contest, It's Circulating The Tapes, the Mystery Science Theater 3000 Watchalong Podcast on The AewchCast. On this episode, Aewch runs some packages and gets the carrots on ice, as he reviews I Accuse My Parents, with the short The Truck Farmer.Watch I Accuse My Parents Right Here!Listen to our episode on Racket Girls Right Here!Social Media: @JustAewch

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Join me in this Trappin Through The stars episode where I recap May's energy, Saturn in Aries, and a new moon!

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

"The biggest mistake is a mindset of scarcity—the fear that there's never enough. The solution is to begin circulating money. Even small acts matter." – Tom LeNoble

Look for the show notes at AnokaCountyHistory.org

Thank God It's Tuesday! We are having a zen day at Spa Mirbeau, hanging out from the Aqua Terrace after a glow facial and plenty of time bouncing from sauna to steam room to shower. We catch up on Intern Aaron's college-y weekend, the latest in documentary TV and play a good old game of Roast or Toast.The Buttonista Show is presented by Michelob Ultra

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in the Prognostic Value of Circulating Biomarkers in Patients Presenting With Acute Chest Pain

Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of AmericanReef, we take a look at the Paletta 500 gallon reef tank 3 months after he replaced most all of the smaller circulating pumps with two larger ones.

There have been reported sightings of ICE agents across the North State on social media. But local organizations and law enforcement agencies report most are likely false alarms. Also, Chico State President Steve Perez sent a message to the campus community last week in response to worries about the school's fiscal situation amid a freeze on federal funding, and the second manual snow survey of the season measured 22 inches of snow depth, only 46 percent of average for the location near Echo Summit.

Do you know someone who is sick right now? There is a "Quademic" going around..  as referred to by health officials. 4 major viruses circulating in the US... Lois Collins with the Deseret News breaks down what you need to know about the viruses impacting Americans.

In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!

This week on The Book Drop, we take a deeper look at the top circulating titles of 2024 for OPL, and discuss what they reveal about our community's awesome reading habits. This is The Book Drop.All the books and resources we talk about in this episode can be found at omahalibrary.org/podcast and here. Happening at the Library: Oregon Trail Live Action | Saturday, Jan. 18 | 1 to 3 p.m. | Saddlebrook Branch and Thursday, Jan. 23 | 6 to 7p.m. | Millard Branch Container Gardening Workshop | Tuesday, Jan. 21 | 10:30 to 11:30 a.m. | Swanson Branch Writer's Workshop | Tuesday, Jan. 21 | 5:30 to 7:30 p.m. | Benson Branch Explore all upcoming events at omahalibrary.org/events.

Circulating cell free DNA fragments are found in your bloodstream when cells die and release what's inside. Some of that DNA is your genetic material and some comes from mitochondria, the power plants of your cells. Johns Hopkins geriatrics expert … Are circulating DNA and inflammation related? Elizabeth Tracey reports Read More »

DNA fragments found in your blood, so called circulating cell free DNA, come from your cells as they die. Both genetic material and DNA from your energy plants, known as mitochondria, can be found, and both are implicated in increased … How does circulating DNA contribute to accelerated aging? Elizabeth Tracey reports Read More »

DNA fragments found circulating in an older person's blood are associated with frailty and Alzheimer's disease, studies by Peter Abadir, a geriatrics expert at Johns Hopkins, and colleagues have shown. These long term studies of several hundred older adults also … Higher levels of your own DNA circulating in your blood may be a problem, Elizabeth Tracey reports Read More »

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. They summarise the results on several important trials such as FASTRACK, ZIRCON, KEYNOTE-564 and IMmotion010. They also discuss the developments on surgical aspects too.To learn more on the highlights discussed in this podcast, you can read the below Articles of the Month, listen to the podcasts or watch the videos.Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914ASCO GU24 special: Prof. Michael Hofman talks about a novel CA IX-targeting peptideASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010Present and future of robotic surgery for RCCThe treatment of locally advanced and metastatic renal cancerFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.

See omnystudio.com/listener for privacy information.

Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

Liquid biopsies and circulating tumor DNA are changing and improving the way cancer is detected and treated. In this episode, Sameek Roychowdhury, PhD, MD, explains the basics of circulating tumor DNA, how it's being used at the James, his lab's clinical trials, and the promising future. “When a normal cell and a cancer die they sheds fragments of their DNA,” he said. “Cancer can be detected in the blood by looking for these fragments and this is becoming an important research tool and treatment tool for the care of cancer patients.” For example, about 50 percent of cancer patients who have a tumor surgically removed will have a recurrence. And it's very difficult to determine which patients will have the recurrence. Minimally invasive liquid biopsies after surgery “helps us stratify and determine patients with a lesser recurrence risk who won't need chemotherapy or immunotherapy treatment versus those patients who need even more treatment than we've normally given them in the past.” Monitoring circulating tumor DNA “also becomes part of the surveillance program and we'll do a precise test every three months that measures fragments in the blood,” Roychowdhury said, adding that finding a recurrence of cancer from these fragments, months before it would appear on more traditional scans “allows us to make a diagnosis about the molecular drivers of the cancer and we can begin treatment earlier and better understand which treatment options will work best.”

This week, Jonathan Sackier is joined by Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps:  (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro  

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, focusing on longevity, pregnancy health, and breast cancer awareness. They explore innovative therapies like ozone treatment and detoxification methods, as well as provide actionable recommendations for couples planning for pregnancy. The conversation also addresses common myths surrounding breast cancer, emphasizing the importance of genetics and regular screenings. In this episode, the conversation delves into various aspects of cancer detection, treatment, and overall health maintenance. The discussion highlights the importance of understanding cancer testing methods, the reality of remission, and innovative therapies that support the immune system. Additionally, the episode emphasizes the significance of lung health through exercise and the critical role of dental hygiene in overall health. The conversation concludes with exciting developments in rejuvenation procedures that promise significant health benefits.   For the audience ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      The mitochondria play a crucial role in energy production and immune response. ·      Ozone therapy can rejuvenate mitochondrial function and aid in detoxification. ·      Frequent sexual activity can improve reproductive health for men. ·      Inositol can help women with PCOS improve their chances of pregnancy. ·      Adequate iodine levels can significantly impact a baby's IQ. ·      Regular exercise is beneficial for both pregnancy and overall health. ·      Avoiding heat exposure is important for male fertility. ·      Genetic testing can provide insights into breast cancer risk. ·      Mammograms are not the only screening method for breast cancer. ·      Circulating tumor cell tests can detect cancer earlier than traditional methods.  ·      Circulating tumor cells are crucial for cancer detection. ·      Remission does not mean the absence of cancer. ·      Innovative therapies can enhance immune response against cancer. ·      Exercise is vital for maintaining lung health. ·      Dental hygiene impacts systemic health significantly. ·      Root canals may lead to latent infections affecting health. ·      Regular exercise improves outcomes for cancer patients. ·      Breathing techniques can enhance lung function during exercise. ·      New rejuvenation procedures show promising results for recovery. ·      Understanding oral bacteria is essential for overall health.   Chapters   00:00 Introduction to Age Hacking and Longevity 10:01 Health Recommendations for Pregnancy: Answering a Listener's Q 21:44 Breast Cancer Awareness and Myths 26:09 Understanding Cancer Detection and Testing 28:50 The Reality of Cancer Remission 30:43 Innovative Cancer Therapies and Immune System Support 35:02 Enhancing Lung Health Through Exercise 43:00 The Importance of Dental Hygiene 48:43 Exciting Developments in Rejuvenation Procedures   Articles, News and Supplements mentioned Breast Cancer BREAST CANCER MYTHS https://www.wkrn.com/news/tennessee-news/breast-cancer-awareness-month-common-myths-about-the-disease/   BREAST CANCER GUIDE EVERYONE SHOULD HAVE https://www.telegraph.co.uk/health-fitness/conditions/cancer/breast-cancer/   NEW TECH FOR CANCER SCREENING https://www.cbsnews.com/chicago/news/doctor-talks-new-technology-importance-of-breast-cancer-screenings/   NEW WAY TO KILL CANCER CELLS https://medicalxpress.com/news/2024-10-cancer-cells-longer-people-breast.html   Healthy Lungs BENEFITS OF EXERCISE FOR PATIENTS WITH LUNG CANCER https://medicalxpress.com/news/2024-10-people-lung-cancer-grueling-evidence.html   HABITS PULMONOLOGISTS ARE BEGGING PEOPLE TO ADOPT AND DITCH https://parade.com/health/the-one-habit-to-adopt-asap-if-you-have-severe-asthma-according-to-pulmonologists   Dental Hygiene DENTAL HEALTH SENSING WITH SONIC TOOTHBRUSH https://medicalxpress.com/news/2024-10-exploring-dental-health-sonic-toothbrush.html   DENTAL HYGIENIST TALKS ABOUT HOW TO SPOT PERIODONTAL DISEASE https://www.buzzfeed.com/meganeliscomb/smell-your-used-floss-tiktok   UGLY YET MOST HIGHLY EFFECTIVE TOOTHBRUSH REVIEWERS HAVE EVER USED https://www.huffpost.com/entry/flossing-toothbrush_l_66fefb0de4b089d324aa50b1/amp   Supplements MOLECULAR HYDROGEN – ENERGY https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-30-ct   MOLECULAR HYDROGEN – CHILL https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-product-h2-chill   TOOTH AND GUM ESSENTIALS TOOTH PASTE https://gladdenlongevityshop.com/products/tooth-gum-essentials-toothpaste-4oz-1?_pos=1&_psq=dental&_ss=e&_v=1.0   TOOTH AND GUM TONICS https://gladdenlongevityshop.com/products/tooth-gum-tonic-18-fl-oz-1?_pos=2&_psq=dental&_ss=e&_v=1.0    UPGRADED IODINE https://gladdenlongevityshop.com/products/upgraded-memory-4fl-oz?pr_prod_strat=e5_desc&pr_rec_id=ec1b1eb28&pr_rec_pid=8125057761519&pr_ref_pid=8125058580719&pr_seq=uniform    ZINC https://gladdenlongevityshop.com/products/zinc-glycinate-120-gels-1?_pos=1&_psq=zinc&_ss=e&_v=1.0    Send your Qs for future episodes! Email: podcast@gladdenlongevity.com   Reach out to us at: Website: https://gladdenlongevity.com/  Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en  LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw 

This week, Jonathan Sackier is joined by Prof. Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps: (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro

Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________

A wild Beyonce conspiracy theory is taking hold, so we're going to explain it. P Diddy's scandals have had people asking who else might be involved, and a lot of attention has landed on Jay Z and Beyonce. Have a listen for all the juicy details...See omnystudio.com/listener for privacy information.

ReferencesChitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway.Clin Cancer Res 2008,14:6364-6370.Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene.Arch Physiol Biochem 2009, 115:58-71.Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.Int J Colorectal Dis 2006, 21:201-208.Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.J Natl Cancer Inst 2002, 94:972-980.Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging.Science 1997, 278:419-424.Doi T, Shimada H, Makizako H, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.Neurobiol Aging 2015, 36:942-947.Calvo D, Gunstad J, Miller LA, et al. Higher serum insulin-like growth factor-1 is associated with better cognitive performance in persons with mild cognitive impairment.Psychogeriatrics 2013, 13:170-174.Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors.Endocr Rev 1994,15:80-101.Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting.Metabolism 1985, 34:391-395.Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr 2012, 66:1146-1152.Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects.Am J Clin Nutr 2005, 82:350-354.Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer.Am J Clin Nutr 2005, 82:277-278.Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.J Clin Endocrinol Metab 2011, 96:2912-2920.Ranke MB, Osterziel KJ, Schweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.Clin Chem Lab Med 2003, 41:1329-1334.Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.J Clin Endocrinol Metab 2014, 99:1712-1721.Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.Horm Res 2003, 60:53-60.Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev 2009,18:1333-1340.Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk.Am J Clin Nutr 2006, 84:1456-1462.Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.Aging Cell 2008, 7:681-687.Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations.J Clin Endocrinol Metab 2009, 94:1732-1739.Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.J Clin Endocrinol Metab 2014, 99:E2308-2316.Svensson J, Carlzon D, Petzold M, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab 2012, 97:4623-4630. .van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The Association of Serum Insulin-Like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: A Population-Based Study.J Clin Endocrinol Metab 2010.Arai Y, Takayama M, Gondo Y, et al. Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age.J Gerontol A Biol Sci Med Sci 2008, 63:1209-1218.Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.J Clin Endocrinol Metab 2005, 90:5937-5941.Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998, 351:1393-1396.Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.Science 1998, 279:563-566.

Remember when I was diagnosed with cancer? remember that thing growing on our kid's neck? Remember when our kid had a seizure? What a year!! Oh and David's too helpful! Stop helping, David!!

Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial efficiency and patient experience. Unlike traditional tissue biopsies, which sample a single tumor site, ctDNA offers a real-time, comprehensive view of the genetic mutations present in the tumor throughout the body. By offering faster, more detailed insights than traditional imaging, ctDNA can identify tumor mutations earlier and help clinicians adjust treatments sooner.In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Dr. Patrick Kelly and Dr. Wael Harb to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Find all of our oncology-related insights on our Insights Hub here.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

WATCH ON YOUTUBE: https://youtu.be/ZNzsha1XJwE.Join Shayn & Orin as we discuss what conspiracy theories are circulating the 2024 election. Thanks for checking out the 14th episode of "Bizarre Inquiries". Don't forget to submit your own bizarre inquiry, clip, or article for us to discuss on the show!Do us a favor and like, follow, share, & leave a review! We appreciate it!.Article: https://www.thedailybeast.com/the-most-outrageous-conspiracy-theories-of-the-2024-election-yet.Do you want join the discussion on this weeks bizarre inquiry?Join the discord and post your thoughts in the "Bizarre Inquiries" channelhttps://discord.com/invite/pPNa84ZEjp.*4 NEW MERCH DESIGNS AVAILABLE NOW!*Use code "CRYPTID10" for 10% off the OMM Merch Store!https://open-minds-media.creator-spring.com/.Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/open_minds_media..REPORT AN ENCOUNTERommencounterreports@outlook.com..Affiliate Link:Chattergeist by Dimension Deviceshttps://dimensiondevices.co.uk/shop.php?affiliate=OpenMindsMediahttps://www.instagram.com/dimension.devices/..Please Check Out:.Bizarre EncountersSocial Media/Email/Donate/Merch/Patreonhttp://linktr.ee/bizarreencounters..Inquiries of our Reality (Shayn)Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/inquiriesofourrealitypodcast..The Framework: UFO Research Center (Orin)https://www.instagram.com/theframeworkufo/..Open Minds Media (OMM)https://linktr.ee/open_minds_media..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..SPONSORS:.IKNOWSQUATCHSpreading the gospel of Squatch with knowledge & fresh merchhttps://www.etsy.com/shop/iknowsquatch?ref=shop_sugghttps://www.instagram.com/iknowsquatch/..CryptoteeologySpecializing in wearable cryptids and monsters and the stories behind them. Discover a relatable monster for any casual occasion.https://www.cryptoteeology.com/https://www.instagram.com/cryptoteeology/https://www.facebook.com/Cryptoteeology..The Snarly Yow Beard & Body ProductsSnarly Products are made exclusively for the Snarly Yow by crafters and local small businesses by hand.https://www.snarlyyow.com/https://www.instagram.com/thesnarlyyowhttps://www.facebook.com/TheSnarlyYow/..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..Intro & Outro By:Socio-Beathttps://distrokid.com/hyperfollow/sociobeat/conundrumhttps://socio-beat.bandcamp.com/..Support this podcast at — https://redcircle.com/bizarre-encounters/donations

Welcome back friends, to another episode of Empower Project Radio. I am so jazzed about this conversation today. We are talking all about MONEY. We're talking about MINDSET. We're talking about high earning and the high earning money blocks that come along with it. Join me, KC Volard, while I pick the brain of global money coach, Kristen Wonch. Check out Kristen's free program offering here. Want to see Kristen live in-person? She's a panelist alongside other multiple 6-figure earners at As She Rises LIVE in Montreal September 21-22, 2024. Do you have your ticket yet? Get yours HERE!The As She Rises Live Event is an Embodiment & Business Conference for Spiritual Entrepreneurs, Mystics, Healers and Visionaries from around the world.An epic, ground shattering and transformational event. Take a screenshot and tag me on Instagram (@iamkcvolard)!Let me know what you're loving!Let's continue the conversation over inside our FREE telegram community - The 7-Figure Coven!

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Weightlifting Talk

Circulating tumor DNA, more commonly referred to as ctDNA, has emerged as an attractive and potentially highly sensitive biomarker for patients with colorectal cancer. But what exactly is ctDNA, does it have any prognostic value for patients with colorectal liver metastasis, and how can it be incorporated into the management of said patients? In this episode from the HPB team at Behind the Knife, listen in on the discussion about ctDNA and its role in the perioperative management of colorectal liver metastasis.   Hosts Anish J. Jain MD (@anishjayjain) is a T32 Research Fellow at the University of Texas MD Anderson Cancer Center within the Department of Surgical Oncology. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center Learning Objectives: -Develop an understanding of what circulating tumor DNA (ctDNA) is.  -Develop an understanding of what makes ctDNA unique from other “tumor markers” like CEA. -Develop an understanding of the prognostic value of ctDNA for colorectal liver metastasis (CRLM).  -Develop an understanding of the current role of ctDNA in the perioperative treatment of patients with CRLM. -Develop an understanding of how ctDNA can be incorporated into future treatment algorithms for patients undergoing hepatic resection for CRLM. Papers Referenced (in the order they were mentioned in the episode): 1)    Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023;277(5):813-820. https://pubmed.ncbi.nlm.nih.gov/35797554/ 2)    Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022;234(4):474-483. https://pubmed.ncbi.nlm.nih.gov/35290266/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Today, you'll learn about the surprising effect our immune system has on our emotional health, a new discovery about the biological clock of plants, and how researchers are rediscovering the science of psychedelics. Stress & Immunity “Mount Sinai Study Shows That Circulating Immune Cells Drawn to the Brain During Stress Can Control Emotional Behaviors.” Mt. Sinai. 2024. “Major Depressive Disorder.” by Navneet Bains & Sara Abdijadid. 2023. “Circulating myeloid-derived MMP8 in stress susceptibility and depression.” by Flurin Cathomas, et al. 2024. Crop Resilience “USC researchers uncover biological circuit that protects plants from extreme conditions.” EurekAlert! 2024. “Climate Change Impacts on Agriculture and Food Supply.” EPA. 2023. “The interplay between the circadian clock and abiotic stress responses mediated by ABF3 and CCA1/LHY.” by Tong Liang, et al. 2024. Psychedelic Scale “An intriguing psychedelic assessment is back from the dead, thanks to Swiss scientists.” by Eric W. Dolan. 2024. “The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.” by Tomas Frymann, et al. 2022. “The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.” by Kurt Stocker, et al. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

#edgarberlanga #danieljacobs #canelo ️️️☎️Edgar Berlanga Vs. Daniel Jacobs